Sanofi Pasteur Head Loew On The Vaccine Unit's Future Growth Drivers
David Loew talked to Scrip about the next-generation meningococcal vaccine candidate MenQuadfi and a monoclonal antibody that may be the first RSV treatment for infants.
You may also be interested in...
The agency is conducting a literature review of 8,000 articles to assess whether certain of eight licensed flu vaccines are more suitable for those 65 and older.
In CEO Paul Hudson's first earnings call at the company's helm, he said he has big goals for driving growth but a deeper strategic update will be outlined to investors on Dec. 10 in Cambridge, Mass.
The market landscape for drugs against respiratory syncytial virus infections, an important risk factor in premature infants and the immunocompromised, may change drastically in the future with numerous potential therapies in the pipeline.